Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis

References

• Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010;60: 393–408.
   PubMed Web of Science ®Google Scholar
• Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol 2011;12:1258–1266.
   PubMed Web of Science ®Google Scholar
• Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d’Etudes des Lymphomes de l’Adulte.Ann Oncol 2000;11:685–690.
   PubMed Web of Science ®Google Scholar
• Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004;15: 129–133.
   PubMed Web of Science ®Google Scholar
• Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007;18:149–157.
   PubMed Web of Science ®Google Scholar
• Bjorkholm M, Hagberg H, Holte H, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 2007;18:1085–1089.
   PubMed Web of Science ®Google Scholar
• Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896–3902.
   PubMed Web of Science ®Google Scholar
• Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516--the Southwest Oncology Group. J Clin Oncol 2009;27:114–119.
   PubMed Web of Science ®Google Scholar
• van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998;91:1178–1184.
   PubMed Web of Science ®Google Scholar
• Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002;13:1099–1107.
   PubMed Web of Science ®Google Scholar
• Lim HY, Thiel E, Glantz MJ. To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin's lymphoma. Curr Opin Oncol 2008;20:495–501.
   PubMed Web of Science ®Google Scholar
• Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006;20:319–332.
   PubMed Web of Science ®Google Scholar
• Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?Blood Rev 2012;26:97–106.
   PubMed Web of Science ®Google Scholar
• Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520–535.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Habermann TM. Diffuse large B-cell lymphoma. Clin Adv Hematol Oncol 2005;3(Suppl.):4–5.
   PubMedGoogle Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013–1022.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma:an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 2012; 23:1267–1273.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Magagnoli M, Frezza G, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma 1999;32:571–576.
   PubMed Web of Science ®Google Scholar
• Bollen EL, Brouwer RE, Hamers S, et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 1997;54:854–859.
   PubMed Web of Science ®Google Scholar
• Hoerni-Simon G, Suchaud JP, Eghbali H, et al. Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A study of 30 cases in a series of 498 patients. Oncology 1987;44:98–101.
   PubMed Web of Science ®Google Scholar
• Smith JA, Glantz M. Statistical and trial design considerations in central nervous system prophylaxis studies. Semin Oncol 2009;36(Suppl. 2):s69–s76.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466–468.
   PubMed Web of Science ®Google Scholar
• Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009;89:577–583.
   PubMed Web of Science ®Google Scholar
• Chihara D, Oki Y, Matsuo K, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma 2011;52:2270–2275.
   PubMed Web of Science ®Google Scholar
• Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010;21:1046–1052.
   PubMed Web of Science ®Google Scholar
• Yamamoto W, Tomita N, Watanabe R, et al. Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol 2010;85:6–10.
   PubMed Web of Science ®Google Scholar
• Lee KW, Yi J, Choi IS, et al. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. Ann Hematol 2009;88:829–838.
   PubMed Web of Science ®Google Scholar
• Keldsen N, Michalski W, Bentzen SM, et al. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma-a multivariate analysis. Acta Oncol 1996;35:703–708.
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003;21:20–27.
   PubMed Web of Science ®Google Scholar
• Kumar A, Vanderplas A, LaCasce AS, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era:findings from a large national database. Cancer 2012;118:2944–2951.
   PubMed Web of Science ®Google Scholar
• Guirguis HR, Cheung MC, Mahrous M, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol 2012;159:39–49.
   PubMed Web of Science ®Google Scholar
• Chua SL, Seymour JF, Streater J, et al. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2002;43:1783–1788.
   PubMed Web of Science ®Google Scholar
• Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet 2005;44:1–31.
   PubMed Web of Science ®Google Scholar
• Kwong Y, Yeung D, Chan J. Intrathecal chemotherapy for hematologic malignancies:drugs and toxicities. Ann Hematol 2009;88:193–201.
   PubMed Web of Science ®Google Scholar
• Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 2010;11:871–79.
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Chong G, Cunningham D, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 2007;18:541–545.
   PubMed Web of Science ®Google Scholar
• Tai WM, Chung J, Tang PL,, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL):pre- and post-rituximab. Ann Hematol 2011;90:809–818.
   PubMed Web of Science ®Google Scholar
• Mitrovic Z, Bast M, Bierman PJ, et al. The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Br J Haematol 2012;157:401–403.
   PubMed Web of Science ®Google Scholar